Neurology drugs

47 drugs with cited findings from FDA review packages and EMA assessment reports. Every figure on every page cites its source document and page.

By condition

Alzheimer's disease (3)Migraine (10)Multiple sclerosis (5)Epilepsy & seizure disorders (9)ATTR amyloidosis (5)Spinal muscular atrophy (4)Parkinson's disease (6)Narcolepsy (4)

By drug class

Anti-amyloid antibodies (2)CGRP inhibitors (migraine) (8)Anti-CD20 therapies (MS) (3)Antisense oligonucleotides (3)RNAi (siRNA) therapeutics (2)Gene therapies (2)

Endpoints & rating scales explained

CDR-SB (Clinical Dementia Rating - Sum of Boxes)Monthly migraine days (MMD)ADAS-Cog ALSFRS-R (ALS Functional Rating Scale)HFMSE (Hammersmith Functional Motor Scale)iADRS (Integrated Alzheimer's Disease Rating Scale)EDSS (Expanded Disability Status Scale)Annualized relapse rate (ARR, MS)6-minute walk test (6MWT)

Kisunla

Eli Lilly and Company · 5530 cited findings

Leqembi

Eisai Co., Ltd. · 5165 cited findings

Austedo

Teva Pharmaceutical Industries Limited · 2386 cited findings

Qalsody

Biogen Inc. · 1930 cited findings

Briumvi

TG THERAPEUTICS, INC · 1744 cited findings

Ajovy

Teva Pharmaceutical Industries Limited · 1669 cited findings

Ocrevus/ocrelizumab

Roche Holding AG · 1620 cited findings

Amvuttra

Alnylam Pharmaceuticals, Inc. · 1525 cited findings

Evrysdi

Roche Holding AG · 1476 cited findings

Vyepti

H. Lundbeck A/S · 1298 cited findings

Wakix

Bioprojet · 1171 cited findings

Atogepant

AbbVie Inc. · 1051 cited findings

Briviact

UCB SA · 1033 cited findings

EMGALITY

Eli Lilly and Company · 1016 cited findings

Onerji

Mitsubishi Tanabe Pharma · 1013 cited findings

Wainzua

AstraZeneca PLC · 986 cited findings

Fampyra

Merz Pharma · 942 cited findings

Fycompa

Eisai Co., Ltd. · 851 cited findings

TEGSEDI

Ionis Pharmaceuticals, Inc. · 842 cited findings

Vyndaqel

Pfizer Inc. · 814 cited findings

Onpattro

Alnylam Pharmaceuticals, Inc. · 794 cited findings

Epidyolex

Jazz Pharmaceuticals plc · 794 cited findings

Kesimpta

Novartis AG · 783 cited findings

Ztalmy

Marinus Pharmaceuticals · 780 cited findings

Zolgensma

Novartis AG · 747 cited findings

Itvisma

Novartis AG · 720 cited findings

lasmiditan

Eli Lilly and Company · 715 cited findings

Ontozry

Angelini Pharma · 687 cited findings

Exelon Patch

Novartis AG · 657 cited findings

Xadago

Zambon · 650 cited findings

rimegepant

Pfizer Inc. · 617 cited findings

Aquipta

AbbVie Inc. · 616 cited findings

Fintepla

UCB SA · 592 cited findings

Xyrem

Jazz Pharmaceuticals plc · 590 cited findings

Ongentys

Bial · 586 cited findings

Ubrelvy

AbbVie Inc. · 584 cited findings

Pitolisant

Bioprojet · 572 cited findings

Aimovig

Novartis AG · 555 cited findings

Spinraza

Biogen Inc. · 541 cited findings

Nurtec-ODT

Pfizer Inc. · 519 cited findings

Inbrija

Merz Pharma · 386 cited findings

Vumerity

Biogen Inc. · 261 cited findings

Lacosamide

UCB SA · 183 cited findings

JZP-258

Jazz Pharmaceuticals plc · 149 cited findings

Ingrezza

NEUROCRINE · 140 cited findings

Kigabeq

Orphelia Pharma · 137 cited findings

perampanel

Eisai Co., Ltd. · 62 cited findings

Educational reference only — not medical or investment advice.